Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec/Elan Submit Tysabri sBLA For Crohn’s Disease

This article was originally published in The Pink Sheet Daily

Executive Summary

Submission includes labeling and risk management plan to address increased risk of progressive multifocal leukoencephalopathy.

You may also be interested in...



Joint Advisory Committee Will Grapple With Risk-Benefit Profile Of Tysabri For Crohn’s

Safety concerns, including the risk of PML, are still relevant considerations, briefing documents state.

Joint Advisory Committee Will Grapple With Risk-Benefit Profile Of Tysabri For Crohn’s

Safety concerns, including the risk of PML, are still relevant considerations, briefing documents state.

Tysabri Crohn’s sBLA Will Get Joint Advisory Committee Review

One of three progressive multifocal leukoencephalopathy deaths in Tysabri clinical database was in a Crohn’s patient.

Related Content

Topics

UsernamePublicRestriction

Register

PS063549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel